tetano
Editor, Senior Moderator
Mol Biol Rep
. 2022 Apr 20.
doi: 10.1007/s11033-022-07455-5. Online ahead of print.
Considerations for the selection of tests for SARS-CoV-2 molecular diagnostics
Huriye Erbak Yılmaz[SUP] 1 2 [/SUP], Evin Iscan[SUP] 3 [/SUP], Ozden Oz[SUP] 3 4 [/SUP], Tuğçe Batur[SUP] 3 [/SUP], Aybike Erdoğan[SUP] 3 [/SUP], Seval Kılıç[SUP] 3 [/SUP], Zeynep Mutlu[SUP] 3 [/SUP], Murat Yılmaz[SUP] 5 [/SUP], Kevin J Spring[SUP] 6 [/SUP]
Affiliations
Abstract
During the course of 2020, the outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread rapidly across the world. Clinical diagnostic testing for SARS-Cov-2 infection has relied on the real-time Reverse Transcriptase Polymerase Chain Reaction and is considered the gold standard assay. Commercial vendors and laboratories quickly mobilised to develop diagnostic tests to detect the novel coronavirus, which was fundamentally important in the pandemic response. These SARS-Cov-2 assays were developed in line with the Food Drug Administration-Emergency Use Authorization guidance. Although new tests are continuously being developed, information about SARS-CoV-2 diagnostic molecular test accuracy has been limited and at times controversial. Therefore, the analytical and clinical performance of SARS-CoV-2 test kits should be carefully considered by the appropriate regulatory authorities and evaluated by independent laboratory validation. This would provide improved end-user confidence in selecting the most reliable and accurate diagnostic test. Moreover, it is unclear whether some of these rapidly developed tests have been subjected to rigorous quality control and assurance required under good manufacturing practice. Variable target gene regions selected for currently available tests, potential mutation in target gene regions, non-standardized pre-analytic phase, a lack of manufacturer independent validation data all create difficulties in selecting tests appropriate for different countries and laboratories. Here we provide information on test criteria which are important in the assessment and selection of SARS-CoV-2 molecular diagnostic tests and outline the potential issues associated with a proportion of the tests on the market.
Keywords: COVID-19; Diagnostic performance; Real-time RT-PCR; SARS-CoV-2; Test selection.
. 2022 Apr 20.
doi: 10.1007/s11033-022-07455-5. Online ahead of print.
Considerations for the selection of tests for SARS-CoV-2 molecular diagnostics
Huriye Erbak Yılmaz[SUP] 1 2 [/SUP], Evin Iscan[SUP] 3 [/SUP], Ozden Oz[SUP] 3 4 [/SUP], Tuğçe Batur[SUP] 3 [/SUP], Aybike Erdoğan[SUP] 3 [/SUP], Seval Kılıç[SUP] 3 [/SUP], Zeynep Mutlu[SUP] 3 [/SUP], Murat Yılmaz[SUP] 5 [/SUP], Kevin J Spring[SUP] 6 [/SUP]
Affiliations
- PMID: 35441938
- DOI: 10.1007/s11033-022-07455-5
Abstract
During the course of 2020, the outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spread rapidly across the world. Clinical diagnostic testing for SARS-Cov-2 infection has relied on the real-time Reverse Transcriptase Polymerase Chain Reaction and is considered the gold standard assay. Commercial vendors and laboratories quickly mobilised to develop diagnostic tests to detect the novel coronavirus, which was fundamentally important in the pandemic response. These SARS-Cov-2 assays were developed in line with the Food Drug Administration-Emergency Use Authorization guidance. Although new tests are continuously being developed, information about SARS-CoV-2 diagnostic molecular test accuracy has been limited and at times controversial. Therefore, the analytical and clinical performance of SARS-CoV-2 test kits should be carefully considered by the appropriate regulatory authorities and evaluated by independent laboratory validation. This would provide improved end-user confidence in selecting the most reliable and accurate diagnostic test. Moreover, it is unclear whether some of these rapidly developed tests have been subjected to rigorous quality control and assurance required under good manufacturing practice. Variable target gene regions selected for currently available tests, potential mutation in target gene regions, non-standardized pre-analytic phase, a lack of manufacturer independent validation data all create difficulties in selecting tests appropriate for different countries and laboratories. Here we provide information on test criteria which are important in the assessment and selection of SARS-CoV-2 molecular diagnostic tests and outline the potential issues associated with a proportion of the tests on the market.
Keywords: COVID-19; Diagnostic performance; Real-time RT-PCR; SARS-CoV-2; Test selection.